Edwards Lifesciences

LifeSci Advisors Expands Digital Health Team with Appointment of Caroline Paul

Retrieved on: 
Thursday, December 1, 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Advisors , an investor relations and corporate communications firm focused on the healthcare sector, today announced the continued expansion of its digital health practice with the appointment of Caroline Paul as Managing Director.

Key Points: 
  • NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Advisors , an investor relations and corporate communications firm focused on the healthcare sector, today announced the continued expansion of its digital health practice with the appointment of Caroline Paul as Managing Director.
  • Carolines background is a perfect fit for our growing digital health franchise, as we continue to add new clients in the sector, said Mike Rice, Cofounder of LifeSci Advisors.
  • Digital health is becoming an important component of the U.S. and global healthcare ecosystems, driven by investment in information technology.
  • Ms. Paul commented, I am thrilled to be joining LifeSci's team to focus on digital health alongside Steve Halper.

Globant acquires Asia Pacific's leading digital commerce specialist eWave, and expands its presence to Australia and Asia

Retrieved on: 
Thursday, November 17, 2022

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company focused on reinventing businesses through innovative technology solutions, announced the acquisition of eWave, an Australian-born digital commerce experience consultancy with strong expertise in Adobe and Salesforce´s commerce solutions. With this acquisition, Globant reinforces its global leadership in digital and cognitive transformation and expands into Australia and several Asian countries.

Key Points: 
  • eWave has offices in Australia, Hong Kong, and Singapore, with a delivery presence in seven countries in the APAC region.
  • With this acquisition, Globant reinforces its global leadership in digital and cognitive transformation and expands into Australia and several Asian countries.
  • With the addition of eWaveto its family of companies, Globant strengthens its expertise in Salesforce Commerce Cloud and Adobe Commerce.
  • "eWaveis APAC's leading digital commerce experience consultancy helping global organizations create competitive advantage and growth.

Greenberg Traurig Expands Corporate Practice in California

Retrieved on: 
Tuesday, October 25, 2022

ORANGE COUNTY, Calif., Oct. 25, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP continues to grow its Corporate Practice with the addition of Yejee Marilyn Kim as of counsel in the Orange County and Los Angeles offices.

Key Points: 
  • Although her practice at Greenberg Traurig will include corporate governance and securities compliance, it will also focus on wider corporate transactional work, such as public and private securities offerings, mergers and acquisitions, and private equity matters.
  • About Greenberg Traurig's Corporate Practice: Greenberg Traurig's Corporate Practice comprises more than 550 lawyers in the United States, Europe, Asia, the Middle East and Latin America who regularly advise public and privately held companies, entrepreneurs and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters.
  • About Greenberg Traurig's California Offices: Greenberg Traurig has more than 200 corporate, entertainment, government law and policy, intellectual property, litigation, real estate, and taxation attorneys in California, located in Los Angeles , Orange County , Sacramento , San Francisco , and Silicon Valley .
  • About Greenberg Traurig: Greenberg Traurig, LLP has more than 2500 attorneys in 43 locations in the United States, Europe, Latin America, Asia, and the Middle East.

Thubrikar Aortic Valve completes initial CE Mark-enabling TAVI-1 Study

Retrieved on: 
Friday, October 21, 2022

Thubrikar Aortic Valve, Inc., announced today that it has completed the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV) in patients with severe aortic stenosis.

Key Points: 
  • Thubrikar Aortic Valve, Inc., announced today that it has completed the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV) in patients with severe aortic stenosis.
  • Williams and Kodali report disclosures with Thubrikar Aortic Valve, Inc.
    Thubrikar Aortic Valve, Inc. is a privately held medical device company near Philadelphia, PA, that has developed a next-generation transcatheter aortic valve, the Optimum TAV, and delivery catheter, collectively called the Optimum TAVI System.
  • Optimum TAV was designed after the natural aortic valve using 30 years of research by the Companys Founder, Dr. Mano Thubrikar.
  • He is the author of The Aortic Valve, a leading textbook covering the fundamentals of valve structure and function.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022

Retrieved on: 
Thursday, October 20, 2022

IRVINE, Calif., Oct. 20, 2022 /PRNewswire/ --Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 after the market closes on Thursday, October 27, 2022, and will host a conference call at 5:00 p.m.

Key Points: 
  • IRVINE, Calif., Oct. 20, 2022 /PRNewswire/ --Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 after the market closes on Thursday, October 27, 2022, and will host a conference call at 5:00 p.m.
  • The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com .
  • Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

Favorable Government Initiatives Will Propel Cardiac Surgery Devices Market to US$ 2.4 Bn By 2032 End | Future Market Insights, Inc.

Retrieved on: 
Tuesday, October 11, 2022

NEWARK, Del., Oct. 11, 2022 /PRNewswire/ -- The global cardiac surgery devices market is predicted to reach a valuation of US$ 2.4 Bn in 2032, with sales growing at a stagnant CAGR of 3.6% from 2022 to 2032. The target market is expected to reach an estimated US$ 1.7 Bn by the end of 2022. The growing prevalence of cardiovascular diseases have resulted in a heightened demand for cardiac surgery devices in the global market over the forecast period.

Key Points: 
  • The growing prevalence of cardiovascular diseases have resulted in aheightened demand for cardiac surgery devices in theglobal market over the forecast period.
  • The expensiveness of cardiac surgery devices along with a strict and extended approval period hinders the growth of the target market.
  • The cardiac surgery devices market in Germany will grow at a 4.9% CAGR during the forecast period.
  • In the South Asian market, India's cardiac surgery devices market will grow at a 2.7% CAGR.

Canary Medical Announces Appointment of Dr. Patrick Verta as Chief Medical Officer

Retrieved on: 
Tuesday, October 11, 2022

Dr. Verta previously served as Vice President of Medical Affairs, Clinical Science and Biometrics at Edwards Lifesciences, Transcatheter Mitral and Tricuspid Therapies division.

Key Points: 
  • Dr. Verta previously served as Vice President of Medical Affairs, Clinical Science and Biometrics at Edwards Lifesciences, Transcatheter Mitral and Tricuspid Therapies division.
  • I also want to recognize Dr. Fred Cushner, who served as our first Chief Medical Officer, and thank him for continuing to support Canary Medical in his new role as Chief Surgical Officer.
  • Previously, he served as Chief Medical Officer for start-up companies Sunshine Heart and Neomend.
  • Canary Medical is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.

Paul Eccles Joins Basis as Managing Partner to Lead Consultancy's Health Division

Retrieved on: 
Wednesday, September 28, 2022

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Basis , a global strategy and insight consultancy headquartered in London with offices in New York City, Los Angeles and Chicago has named Paul Eccles as Managing Partner of Basis Health in New York.

Key Points: 
  • NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Basis , a global strategy and insight consultancy headquartered in London with offices in New York City, Los Angeles and Chicago has named Paul Eccles as Managing Partner of Basis Health in New York.
  • The announcement comes as the company continues its rapid growth and commercialization in its health division, Basis Health .
  • "As we continue to grow Basis Health, adding Paul to the team only strengthens our commitment to invest and deliver thoughtful and strategic guidance to our people, partners and clients."
  • Basis Health partners with LifeScience companies to inform and drive strategic decisions, powered by research and analytics, supporting across an expansive range of business needs and therapeutic areas.

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

Retrieved on: 
Saturday, September 17, 2022

The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).
  • The PASCAL system further demonstrated significant and sustained MR 1+ with 83.7 percent of patients at MR 1+ at six months.
  • The CLASP IID trial is a prospective randomized controlled trial comparing the safety and effectiveness of the PASCAL system to the MitraClip system.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

Retrieved on: 
Thursday, September 15, 2022

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcathetervalve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcathetervalve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).
  • With FDA approval of the PASCAL system, US clinicians now have an additional option for treating patients with severe mitral regurgitation."
  • Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve isused in the treatment of mitral regurgitation.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.